Clinical Scorecard: Considering Interventional Glaucoma Management
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Interventional techniques including genetic testing, selective laser trabeculoplasty (SLT), and minimally invasive glaucoma surgery (MIGS) to manage intraocular pressure (IOP) and disease progression. |
| Target Population | Patients with open-angle glaucoma and ocular hypertension. |
| Care Setting | Ophthalmology and optometry practices. |
Key Highlights
- Genetic testing for glaucoma aids in risk assessment and management.
- SLT provides long-term disease control and reduces need for drops and surgeries.
- MIGS procedures offer minimal disruption and rapid recovery.
- FDA-approved devices include Durysta and iDose TR for sustained medication release.
- Nutraceuticals may support ocular health in glaucoma patients.
Guideline-Based Recommendations
Diagnosis
- Utilize genetic testing for risk assessment of glaucoma progression.
Management
- Consider SLT as a first-line treatment for open-angle glaucoma and ocular hypertension.
Monitoring & Follow-up
- Educate patients on the importance of follow-up appointments based on genetic risk.
Risks
- Monitor for conversion from ocular hypertension to glaucoma.
Patient & Prescribing Data
Patients diagnosed with glaucoma or at risk of developing glaucoma.
Incorporate both surgical and pharmacological options for comprehensive management.
Clinical Best Practices
- Identify candidates for MIGS and educate them on expectations.
- Encourage adherence to follow-up appointments for ongoing management.
- Consider dietary and nutraceutical support for glaucoma patients.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.